Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,736 shares of the medical research company’s stock after selling 886 shares during the period. Fisher Asset Management LLC owned about 0.33% of Bio-Rad Laboratories worth $31,028,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. First Eagle Investment Management LLC increased its position in shares of Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after acquiring an additional 634,311 shares during the last quarter. Swedbank AB acquired a new stake in Bio-Rad Laboratories during the 1st quarter valued at approximately $1,824,000. Principal Financial Group Inc. increased its holdings in Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after purchasing an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. raised its position in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of Bio-Rad Laboratories by 320.6% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 3,663 shares of the medical research company’s stock valued at $1,000,000 after buying an additional 2,792 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Insider Buying and Selling

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. The trade was a 80.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their position. The disclosure for this sale can be found here. 17.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on BIO shares. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target for the company. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada upped their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Citigroup lifted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average target price of $391.80.

Bio-Rad Laboratories Trading Up 0.6 %

Bio-Rad Laboratories stock opened at $338.24 on Wednesday. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $387.99. The firm’s 50-day moving average is $340.63 and its 200-day moving average is $316.68. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The company has a market cap of $9.47 billion, a P/E ratio of -12.38 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. The company had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.33 earnings per share. On average, equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.